Great ?'s Sidebar.

"Do we need a P3 (larger group) after this?"

Most likely a P3 will be needed prior to emergency approval, IMO. Apabetalone has never been tested in this patient population/for this indication. So regulatory agencies likely will require P3.

"Question to our knowledgeable followers, how many days after the four weeks will they know the effect of ABL and what parts of the body, heart, lungs, kidneys showed improvement? Seems, in four weeks either the patient gets better or not."

This is an open label trial, so everyone knows who is getting apabetalone. Very likely that any improvements will be seen prior to the end of the 4 week dosing period. As for what organs are showing improvement, this may depend on what endpoints that they plan to look at in the trial. When the full trial protocol is posted soon to clinicaltrials.gov, hopefully we get additional insight on this. 

"Interesting, i recall in the early 12 or 13 week studies, ABL needed about 5 to 6 weeks to begin HDL production.  There are so many benefits with ABL.  Hope this study opens the doors.  We have longed to see this."

For apoAI/HDL production, there did seem to be a lag period. However, as detailed here, effects on circulating plasma proteins (and therefore transcriptional changes) are detected within a 12 hours after a single dose.

BDAZ